Literature DB >> 24528049

Epidermal growth factor receptor mutations in non- small cell lung cancers in a multiethnic malaysian patient population.

Chong-Kin Liam1, Hwong-Ruey Leow, Soon-Hin How, Yong-Kek Pang, Keong-Tiong Chua, Boon-Khaw Lim, Nai-Lang Lai, Yeh-Chunn Kuan, Jayalakshmi Pailoor, Pathmanathan Rajadurai.   

Abstract

BACKGROUND: Mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) in non- small cell lung cancer (NSCLC) are predictive of response to EGFR-targeted therapy in advanced stages of disease. This study aimed to determine the frequency of EGFR mutations in NSCLCs and to correlate their presence with clinical characteristics in multiethnic Malaysian patients.
MATERIALS AND METHODS: In this prospective study, EGFR mutations in exons 18, 19, 20 and 21 in formalin-fixed paraffin-embedded biopsy specimens of consecutive NSCLC patients were asessed by real-time polymerase chain reaction.
RESULTS: EGFR mutations were detected in NSCLCs from 55 (36.4%) of a total of 151 patients, being significantly more common in females (62.5%) than in males (17.2%) [odds ratio (OR), 8.00; 95% confidence interval (CI), 3.77-16.98; p<0.001] and in never smokers (62.5%) than in ever smokers (12.7%) (OR, 11.50; 95%CI, 5.08-26.03; p<0.001). Mutations were more common in adenocarcinoma (39.4%) compared to non-adenocarcinoma NSCLCs (15.8%) (p=0.072). The mutation rates in patients of different ethnicities were not significantly different (p=0.08). Never smoking status was the only clinical feature that independently predicted the presence of EGFR mutations (adjusted OR, 5.94; 95%CI, 1.94- 18.17; p=0.002).
CONCLUSIONS: In Malaysian patients with NSCLC, the EGFR mutation rate was similar to that in other Asian populations. EGFR mutations were significantly more common in female patients and in never smokers. Never smoking status was the only independent predictor for the presence of EGFR mutations.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24528049     DOI: 10.7314/apjcp.2014.15.1.321

Source DB:  PubMed          Journal:  Asian Pac J Cancer Prev        ISSN: 1513-7368


  5 in total

1.  EGFR mutation incidence in non-small-cell lung cancer of adenocarcinoma histology: a systematic review and global map by ethnicity (mutMapII).

Authors:  Anita Midha; Simon Dearden; Rose McCormack
Journal:  Am J Cancer Res       Date:  2015-08-15       Impact factor: 6.166

2.  Influence of Autophagy Inhibition on Lung Adenocarcinoma Cell Migration and Invasion Ability, and Efficacy of Gefitinib.

Authors:  Ying Liu; Yun Du
Journal:  Technol Cancer Res Treat       Date:  2021 Jan-Dec

3.  Outcomes of Patients with EGFR-Mutant Advanced NSCLC in a Developing Country in Southeast Asia.

Authors:  Soon Hin How; Chong Kin Liam; Muhammad Adil Zainal Abidin; Harissa H Hasbullah; Lye Mun Tho; Gwo Fuang Ho; Ibtisam Muhamad Nor; Yong Kek Pang; Kean Fatt Ho; Muthukkumaran Thiagarajan; Roziana Ariffin; Azlina Samsudin; Azza Omar; Sin Nee Tan; Choo Khoon Ong; Sing Yang Soon; Mau Ern Poh
Journal:  Cancer Manag Res       Date:  2022-06-16       Impact factor: 3.602

4.  Gefitinib as first line therapy in Malaysian patients with EGFR mutation-positive non-small-cell lung cancer: A single-center retrospective study.

Authors:  Matin Mellor Abdullah; Amit Bhat; Ahmad Kamal Mohamed; Foo Yoke Ching; Nida Ahmed; Sandeep Gantotti
Journal:  Oncol Lett       Date:  2016-03-09       Impact factor: 2.967

Review 5.  Clinical efficacy and safety of afatinib in the treatment of non-small-cell lung cancer in Chinese patients.

Authors:  Lei-Yun Wang; Jia-Jia Cui; Ao-Xiang Guo; Ji-Ye Yin
Journal:  Onco Targets Ther       Date:  2018-01-24       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.